Media Citations

Our Reports

A wide portfolio of market research reports in the healthcare industry

latest reports

  • Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue  Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))

    Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))

    January 2020

    According to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to  diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions.  In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness. The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.  Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms. In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel® (2018), MACI (2016), Stempeucel® (2016) and Strimvelis® (2016). Further, several such therapies are presently being evaluated across 540 active clinical trials worldwide. This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors. Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term. Scope of the Report The “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue  Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue  placenta, peripheral blood, stromal cells  and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. In addition, information on the various technology platforms being actively used for the development of stem cell therapies has been provided. Identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas). Detailed profiles of the key industry players engaged in the development of stem cell-based therapies, featuring a brief overview of the company (such as year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available)), details of their respective product portfolio and an informed future outlook. An assessment of over 20 commonly targeted therapeutic indications and details of stem cell-based therapies being developed to treat the same conditions, highlighting disease specific epidemiological facts, contemporary methods of diagnosis, and currently available treatment options and their side-effects. An analysis of potential growth opportunities for stem cell therapies across different therapeutic areas in the established / emerging regions, based on the Ansoff growth model. An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute, funding institute center, funding institute center, support period, spending categorization, funding mechanism, grant type, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of stem cell (based on origin, source, potency and lineage) and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of indications under investigation. A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials. A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers (such as year of establishment, company size, location of headquarters and manufacturing facilities), scale of stem cell manufacturing (commercial, clinician and preclinical), services offered in addition to manufacturing (culture development / set up, stem cell identification / validation, stem cell banking, regulatory consultancy, fill / finish, cryopreservation and stem cell logistics), source of  stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner. A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.  An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization (prior to product launch, post-marketing, and near patent expiry), and the key strategies that have been adopted by drug developers for the commercialization of their proprietary product candidates.  An analysis of contemporary trends, as observed on the Google Trends portal, for the period 2015-2019 and insights from the recent news articles related to stem cell therapies indicating the increasing popularity of this upcoming field of research. One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for stem cell therapies over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved stem cell therapies. The report also features the likely distribution of the current and forecasted opportunity within stem cell therapies market across [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end-users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: William L Rust (Founder and Chief Executive Officer, Seraxis) Xuejun Huang Parsons (Chief Executive Officer, Xcelthera) Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem) Kikuo Yasui (Director and Chief Operating Officer, Heartseed) Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock) Gilles Devillers (President, Bio Elpida) Fiona Bellot (Business Development Manager, Roslin Cell Therapies)   David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota) Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more
  • Bioavailability Enhancement Technologies and Services Market, 2020-2030

    Bioavailability Enhancement Technologies and Services Market, 2020-2030

    January 2020

    Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability (via the 505(b)(2) pathway), the demand for novel bioavailability enhancement methods has grown significantly. To cater to this increasing demand, several contract manufacturers and technology providers have emerged in this domain. With more than 150 companies offering technologies / services for bioavailability enhancement, the market is highly fragmented; having said that, several mergers / acquisitions have also taken place as stakeholders strive to broaden their respective service portfolios. A number of players have developed novel, state-of-the art technologies to maintain a competitive edge in this rapidly emerging market. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace. In fact, since 2010, more than 4,000 articles, evaluating various bioavailability enhancement technologies have been published across several reputed journals. In addition, more than 6,000 patents have been filed post 2010, providing a significant scientific push to the development of novel approaches. Scope of the Report The ‘Bioavailability Enhancement Technologies and Services Market, 2020-2030’ report provides a comprehensive study on the current scenario of technologies and contract services related to bioavailability enhancement. The study features an elaborate discussion on the novel approaches adopted by different players offering solutions for altering the bioavailability of various drugs. Amongst other elements, the report features: An overview of the current market landscape, featuring a comprehensive list of over 150 active contract services / technology providers, and a detailed analysis based on a number of parameters, such as geographical location of the company, approach adopted for bioavailability enhancement (size reduction, solid dispersion, lipid based methods and other novel approaches), type of dosage forms (solid, liquid, semi-solid, others), route of drug administration (oral, injectable, inhalation and topical). Elaborate profiles of key players (identified on the basis of the breadth of their respective service portfolios) that are offering bioavailability enhancement services. Each profile features an overview of the company, its financial performance (if available), services portfolio, recent collaborations and the future outlook of the company. An analysis of ongoing clinical studies evaluating the bioavailability of various drug compounds. The chapter features a comprehensive view on the focus areas of these clinical studies, highlighting the key players involved. A review of the published scientific literature on bioavailability enhancement technologies, highlighting the heightened research activity and the focus areas of research groups across different types of bioavailability enhancement technologies. A detailed analysis of over 6,000 patents that have been filed related to bioavailability enhancement technologies. The study presents a high-level view on the valuation of these patents and also highlights the emerging trends related to the innovation in this domain. An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, co-service agreements, manufacturing and service agreements, and other relevant types of deals. A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large sized companies; the benchmark analysis provides a means to compare the existing capabilities within respective peer groups and help industry stakeholders identify ways to achieve a competitive edge over contemporary players. A detailed estimation of the likely demand for bioavailability enhancement technologies / services. It provides a comprehensive view, in terms, of the annual number of projects, that are likely to require bioavailability enhancement over the period 2018-2030. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as likely number of candidates in BCS II and IV, likely adoption rates of bioavailability enhancement approaches, expected trend in outsourcing and likely pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. To account for the uncertainties associated with the expected future demand and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more
  • Antibody Contract Manufacturing Market, 2020 - 2030

    Antibody Contract Manufacturing Market, 2020 - 2030

    January 2020

    Since the approval of Orthoclone OKT3® in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies; recent approvals include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). Owing to their high specificity and the favorable safety profile associated with the therapeutic use of such molecules, antibody based interventions presently constitute the largest class of biologics in the industry. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragments-based products, are steadily gaining traction. Further, owing to legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements, outsourcing antibody production operations is a popular trend.  The antibody contract manufacturing market is highly competitive, featuring companies of all sizes, some of which claim to offer end-to-end solutions, ranging from antibody development to commercial production. Historical and prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. This dependence on outsourcing can be attributed to the high cost and time investment required to establish the necessary infrastructure and expertise in biologics. The competition among contract manufacturing organizations (CMOs) engaged in this domain is high, with the availability of cutting-edge tools and technologies being one of the key differentiating factors that grant a competitive advantage over other players. Therefore, in order to establish a strong foothold in the market and also meet the growing demand for antibody therapeutics / reagents, CMOs are actively expanding their capacities and capabilities. Scope of the Report The antibody production report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes: A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.  A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation). A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups. An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area. An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility. An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).  Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength. Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.   A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.  A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  One of the key objectives of the report was to estimate the existing market size and the future growth potential within the antibody contract manufacturing market. Based on multiple parameters, such as projected growth of overall antibody-based products market, cost of goods sold and direct manufacturing costs, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: Dietmar Katinger, Chief Executive Officer, Polymun Scientific  David C Cunningham, Director Corporate Development, Goodwin Biotechnology    Claire Otjes, Assistant Marketing Manager, Batavia Biosciences All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more

trending reports

press releases

  • Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis

    November 2019

    The approval of KYMRIAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list of offerings.  Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry. To order this 500+ page report, which features 160+ figures and 250+ tables, please visit this link Key Market Insights  More than 160 organizations claim to be engaged in cell therapy manufacturing The market landscape is dominated by industry players, representing more than 60% of the total number of stakeholders. Amongst these, over 55 are large or mid-sized firms (having more than 50 employees).  100+ players focused on T-cell and stem cell therapies Most of these players are focused on manufacturing T-cell therapies, including CART, TCR or TILs. It is worth highlighting that more than 35 organizations claim to have necessary capabilities for the manufacturing of both types of therapies. Presently, 70+ companies have commercial scale capacity  As majority of the cell therapy products are in clinical trials, the demand is high at this scale. However, it is worth noting that several players (~50%) have already developed commercial scale capacity for cell therapies.  Europe is currently considered a current hub for cell therapy production More than 220 manufacturing facilities have been established by various players, worldwide; of these, 35% are in Europe, followed by those based in North America. Other emerging regions include Australia, China, Japan, Singapore, South Korea and Israel.  50+ facility expansions reported between 2015-2019 More than 85% of the expansions are related to setting up of new facilities across different regions. Maximum expansion activity was observed in the US and in certain countries within the Asia Pacific regions.  20+ companies offer automated solutions to cell therapy developers  Players that claim to offer consultancy services related to automation include (in alphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics, GE Healthcare and Terumo BCT. Further, we identified players, namely (in alphabetical order) Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Invetech, KMC Systems, Mayo Clinic Center for Regenerative Medicine and RoosterBio, that offer consultancy solutions related to automation.  Partnership activity has grown at an annualized rate of 16%, between 2014 and 2018 More than 200 agreements have been inked in the last 5 years; majority of these were focused on the supply of cell-based therapy products for clinical trials. Other popular types of collaboration models include manufacturing process development agreements (16%), services agreements (12%) and acquisitions (10%). By 2030, developed geographies will capture over 60% of the market share Asia Pacific is anticipated to capture the major share (~36%) of the market by 2030. It is also important to highlight that financial resources, technical expertise and established infrastructure is likely to drive cell therapy manufacturing market in Europe, which is estimated to grow at a CAGR of ~26%.  To request a sample copy / brochure of this report, please visit this link     Key Questions Answered What is the global demand for cell-based therapies?  Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world? What are the major recent developments (such as partnerships and expansions) in this industry?  What kind of partnership models are commonly adopted by stakeholders in this domain?  What is the current, installed contract manufacturing capacity for cell therapies? What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies?  What are the key parameters governing the cost of cell therapy manufacturing? What are important technology platforms (available / under development) for cell therapy development and manufacturing?  What are the key drivers and growth constraints in cell therapy manufacturing market? How is the current and future market opportunity likely to be distributed across key market segments? The USD 10+ billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments: Type of therapy T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies) Dendritic cell therapies Tumor cell therapies Stem cell therapies Source of cells Autologous  Allogeneic  Scale of operation Clinical  Commercial  Purpose of manufacturing Contract manufacturing In-house manufacturing Key geographical regions  North America Europe Asia Pacific Rest of the world The report features inputs from eminent industry stakeholders, according to whom the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts: Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR) Tim Oldham (Chief Executive Officer, Cell Therapies) Gerard MJ Bos (Chief Executive Officer, CiMaas) Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies) Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics) Arik Hasson (Executive VP Research and Development, Kadimastem) Gilles Devillers (General Manager, Bio Elpida) Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, Center of Excellence for Cellular Therapy / C3i) Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) Fiona Bellot (Business Development Manager, RoslinCT) Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota) The research covers profiles of key players (industry and non-industry) that offer manufacturing services for cell-based therapies, featuring a company overview, information on manufacturing facilities, and recent collaborations.  BioNTech Innovative Manufacturing Services Cell Therapies Cell and Gene Therapy Catapult Center for Cell and Gene Therapy, Baylor College of Medicine Centre for Cell Manufacturing Ireland, National University of Ireland Clinical Cell and Vaccine Production Facility, University of Pennsylvania Cognate BioServices FUJIFILM  Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital Hitachi Chemical  KBI Biopharma Laboratory for Cell and Gene Medicine, Stanford University Lonza MaSTherCell MEDINET Molecular and Cellular Therapeutics, University of Minnesota Newcastle Cellular Therapies Facility, Newcastle University Nikon CeLL innovation Rayne Cell Therapy Suite, King’s College London Roslin Cell Therapies Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine Sydney Cell and Gene Therapy WuXi Advanced Therapies For additional details, please visit  https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html or email sales@rootsanalysis.com  You may also be interested in the following titles:  Cell and Advanced Therapies Supply Chain Management Market, 2019-2030 RNAi Therapeutics Market (2nd Edition), 2019 – 2030 Gene Therapy Market (3rd Edition), 2019 – 2030 Stem Cell Therapy Contract Manufacturing Market, 2019-2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com

    ...read more
  • The global automotive lithium-ion battery market is projected to reach USD 95.3 Billion by 2030, growing at an annualized rate of 17.1 %, claims Roots Analysis

    November 2019

    The growing global urgency to reduce carbon footprint, coupled to the long life and low maintenance requirements of lithium ion batteries, have enabled this relatively new class of portable power sources to effectively penetrate the automotive market Roots Analysis has announced the addition of “Automotive Lithium-Ion Battery Market, 2019-2030” report to its list of offerings.  Owing to their numerous benefits, the sales of lithium ion battery powered cars have grown by more than 10 times over the period 2013-2019. In addition, the anticipated ban on IC engine vehicles by 2030 is likely to further drive the demand for these batteries within the automobile industry.   To order this 100+ page report, which features 60+ figures and 100+ tables, please visit this link  Key Market Insights  Lithium Nickel Manganese Cobalt Oxide (NMC) batteries presently capture the highest share  NMC batteries, primarily used in buses and cars, represent more than one-third of overall market share (in terms of revenues generated from battery sales). Other popular battery types that are expected to witness significant growth in the foreseen future, are lithium titanium oxide (LTO) batteries and lithium iron phosphate batteries (LiFEPO4).  Electric four wheelers are expected to capture over 50% of the market by 2030 In developed geographies, e-buses and e-cars are likely to drive significant growth in battery sales; specifically, e-cars are anticipated to dominate the market throughout the forecast period. On the other hand, lithium-ion battery powered three wheelers are anticipated to contribute to revenue generation in developing nations, such as India, China and Africa. Currently, China holds the top position among the world’s largest manufacturers of lithium ion batteries for automotive applications.   By 2025, the global lithium-ion battery production capacity could reach up to 1,112 GWh  In 2019, lithium ion batteries with 48-99 WH capacity are anticipated to capture over 30% of the global market. However, batteries with a capacity of more than 250 KWh are expected to grow at a rapid rate, due to the growing number of electric buses across the world, specifically, in the US, UK and China. To request a sample copy / brochure of this report, please visit this link     Key Questions Answered What are the popular types of lithium-ion batteries? How are lithium-ion batteries more profitable than other batteries?  Who are the key players within the automotive lithium-ion battery market?  What is the current and future capacity of lithium-ion batteries? What are the key geographies with manufacturing capabilities for lithium-ion battery powered electric vehicles? How is the current and future market opportunity likely to be distributed across key market segments? How is the current and forecasted opportunity likely to be distributed across two wheeler-, three wheeler- and four wheeler electric vehicles? The USD 95.3 billion (by 2030) financial opportunity within the global automotive lithium-ion battery market has been analyzed across the following segments: Battery Type Lithium Nickel Manganese Cobalt Batteries Lithium Titanium Oxide Batteries Lithium Iron Phosphate Batteries Vehicle Type Two Wheelers Three Wheelers Four Wheelers Battery Capacity 5-47 Wh 48-99 Wh 100-250 KWh More than 250 KWh Key Geographical Regions  North America Europe Asia-Pacific RoW (Latin America, Middle East, and Africa) The research covers profiles of key players that offer contract manufacturing services for medical devices, featuring an overview of the company, its service portfolio, details on manufacturing facilities, and an informed future outlook.  BYD  DENSO  Exicom Power Solutions  Toshiba  LG Chem Panasonic  Samsung SDI  Contemporary Amperex Technology  A123 Systems  Johnson Controls  Oxis Energy StoreDot  NOHMs Technologies GoZero Mobility RELiON Battery For additional details, please visit  https://www.rootsanalysis.com/reports/view_document/automotive-li-ion-batteries-market/273.html or email sales@rootsanalysis.com  You may also be interested in the following titles:      Next-Generation Batteries Market, 2018-2030 Smart Grids Infrastructure Market, 2018-2030  Thin Film Photovoltaics Market, 2017-2030 Grid Scale Energy Storage Technologies Market, 2017-2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com

    ...read more
  • The cell and advanced therapies supply chain management market is anticipated to grow at an annualized rate of 11% till 2030, claims Roots Analysis

    November 2019

    Over time, biopharmaceutical companies have realized the importance of integrating advanced software into the cell and advanced therapies supply chain. Such upgrades have demonstrated the ability to offer both time and cost saving Roots Analysis has announced the addition of the “Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030” report to its list of offerings.  The cell and advanced therapies supply chain is complex, with several legacy challenges, such as those related to patient scheduling, resource planning, inventory management, and deliverable tracking. A number of innovative, software-enabled systems are available / under development to mitigate the aforementioned concerns and simplify the management of biopharmaceutical supply chains.  To order this 420+ page report, which features 150+ figures and 350+ tables, please visit this link  Key Market Insights  Over 160 software-enabled supply chain management systems are currently available  Of these, more than 25% are inventory management systems (IMS), which are primarily used for tracking inventory, orders, sales and deliveries. Examples include (in alphabetical order) ATiM Software, Benchling Inventory, CryoTrackIMS, Cryotrax, CTM-STAR™, Lynx Mobile®, Mosaic FreezerManagement, and Stafa Apheresis. ~80% of marketed solutions are used in collection centers and sample storage warehouses Further, about 49% of such systems are being implemented to streamline manufacturing operations of cell and advanced therapies Cloud-based deployment is gradually gaining popularity  Stakeholders claim that such deployment methods can be rapidly provisioned with minimal management effort (often over the internet), allowing for faster implementation. At present, about 47% of the software systems are being deployed via cloud; examples include (in alphabetical order) Chronicle™ automation software, Cryoportal®, evo.is®, PAS-X MES, STARLIMS, tempmate®-CLOUD, and TrakCel™.   Around 57% of the stakeholders in this industry are based in the US This can be attributed to the increasing interest in cell and advanced therapies in this region, making North America the current hub of innovation in this field. It is followed by players in the EU (35%) and Asia Pacific (8%).  2,600+ tweets focused on the increasing interest and ongoing efforts of industry stakeholders  Social media analysis revealed that many biopharmaceutical developers are adopting software-enabled supply chain management solutions with increasing enthusiasm. In fact, many of the tweets were related to the ability of such systems to resolve the challenges associated with large volumes of supply chain data. Over 10 supply chain orchestration solutions are currently available in the market These solutions have demonstrated the ability to efficiently integrate core software systems, in order to offer needle-to-needle traceability within complex supply chains.  ~USD 650 million has been invested by both private and public investors, since 2014 Of this, close to USD 300 million was raised through venture capital funding rounds, representing 47% of the total capital raised. Further, there were five instances of IPOs / secondary offerings, accounting for USD 280 million in raised capital. Partnership activity has increased at an annualized rate of 14%  In fact, around 55% of the reported deals were established post 2016; the maximum partnership activity was observed in 2018. Majority of these agreements (75+) were observed to be focused on platform integration or the establishment of service alliances.  North America and Europe are anticipated to capture over 85% market share by 2030  In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.  To request a sample copy / brochure of this report, please visit this link Key Questions Answered What are the trending software solutions for the management of cell and advanced therapies supply chain? Who are the leading industry and non-industry players in this domain? What are the key challenges faced by various stakeholders in this domain? What kind of partnership models are commonly adopted by stakeholders in this industry? Who are the key investors in this field? What is the current and likely future cost saving opportunities associated with supply chain management solutions? How is the current and future market opportunity likely to be distributed across key market segments and geographies?  What factors are likely to influence the evolution of this upcoming market? The financial opportunity within the cell and advanced therapies supply chain management market has been analyzed across the following segments: Application area Donor eligibility assessment Sample collection Manufacturing Logistics Patient verification and treatment follow-up Type of software solution Cell orchestration platform Enterprise manufacturing system Inventory management system Laboratory information management system Logistics management system Patient management system Quality management system Tracking and tracing system Mode of Deployment Cloud-based solution On-premises solution End user  Biobank Cell therapy lab Hospital Research institute Commercial organization Key geographical regions  North America Europe Asia Pacific The report features inputs from eminent industry stakeholders, according to whom software-enabled supply chain management systems have the potential to eliminating risks, and reducing time and capital investment in the cell and advanced therapy development process. The report includes detailed transcripts of discussions held with the following experts: Martin Lamb (Chief Business Officer, TrakCel) Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult) Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific) Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson) and Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) The research includes elaborate profiles of key stakeholders (listed below), featuring a brief company overview, its financial information (if available), and a detailed description of its platform(s), recent developments and an informed future outlook. Be The Match BioTherapies® Brooks Life Sciences  Clarkston Consulting Cryoport  Haemonetics  Hypertrust Patient Data Care Lykan Bioscience  MAK-SYSTEM  MasterControl  SAP  SAVSU Technologies sedApta Group Stafa Cellular Therapy Title21 Health Solutions TraceLink  TrakCel Vineti For additional details, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html or email sales@rootsanalysis.com  You may also be interested in the following titles: Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors) Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 Stem Cell Therapy Contract Manufacturing Market, 2019-2030 Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 Cell and Gene Therapy CROs Market, 2018-2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com

    ...read more

The Roots Analysis Edge

200 +

Reports

40 +

Major Pharma Markets

400 +

Clients

50 +

Analytical Frameworks

Consulting

Market insights from across the industry value chain tailored to meet your business needs

  • All
  • Drug Discovery
  • Research & Development
  • Commercialization
  • Affilated services
  • Pipeline Tracking

  • Therapy Area Assessment

  • Clinical Trial Tracking

  • KOL Selection

  • Publication Analysis

  • Investment Analysis

  • Market Assessment

  • Deal Tracking

  • Competitive Profiling

  • Commercial Strategy and Business Development

Why Choose Us?

We are your partners with no equity

We fit in your budget

We love what we do

chance to prove ourselves

Best in class quality of work

Most trusted consulting partner in the industry